BLT offers a potential curative treatment for Hep C at $150 mill...

BLT offers a potential curative treatment for Hep C at $150 mill MC and 3 other programs around the preclinical stages. Gilead offers a potential curative treatment at $128 billion and paid 11 billion for the tech. Even if the outcomes from both treatments are on par, the Fed/medical insurance companies doing the reimbursing for treatment would have a massive advantage in the vastly cheaper option of BLT. The other element is that success in this program would validate BLT's tech and open a plethora of new opportunities for this little company.